Which has better valuation & earnings, BNTX or LNTH?

Lantheus has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.06 -$1.29B -$5.88 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.30

Is BNTX or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Lantheus 18.05% 29.32% 15.00%

Does the media refer more to BNTX or LNTH?

In the previous week, BioNTech and BioNTech both had 2 articles in the media. BioNTech's average media sentiment score of 1.38 beat Lantheus' score of 0.63 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, LNTH or ROIV?

Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.43 $233.56M $4.15 25.30 Roivant Sciences $8.26M 2,629.78 -$299.77M -$0.60 N/A

Is LNTH or ROIV more profitable?

Lantheus has a net margin of 18.05% compared to Roivant Sciences' net margin of -3,629.19%. Lantheus' return on equity of 29.32% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media prefer LNTH or ROIV?

In the previous week, Roivant Sciences had 9 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Roivant Sciences and 2 mentions for Lantheus. Roivant Sciences' average media sentiment score of 1.55 beat Lantheus' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, INSM or LNTH?

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 34.40 -$1.28B -$5.75 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.30

Is INSM or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Lantheus 18.05% 29.32% 15.00%

Does the media favor INSM or LNTH?

In the previous week, Insmed had 14 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Insmed and 2 mentions for Lantheus. Insmed's average media sentiment score of 1.21 beat Lantheus' score of 0.63 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, MRNA or LNTH?

Lantheus has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 11.46 -$2.82B -$8.15 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.30

Is MRNA or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Lantheus 18.05% 29.32% 15.00%

Does the media prefer MRNA or LNTH?

In the previous week, Moderna had 14 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Moderna and 2 mentions for Lantheus. Moderna's average media sentiment score of 0.65 beat Lantheus' score of 0.63 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, VTRS or LNTH?

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.31 -$3.51B -$0.26 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.30

Is VTRS or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Lantheus 18.05% 29.32% 15.00%

Does the media prefer VTRS or LNTH?

In the previous week, Viatris had 3 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Viatris and 2 mentions for Lantheus. Viatris' average media sentiment score of 0.80 beat Lantheus' score of 0.63 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantheus (LNTH) Competitors

$105.00 +0.33 (+0.32%)

As of 03:17 PM Eastern

Compare

LNTH vs. BNTX, ROIV, INSM, MRNA, and VTRS

Should you buy Lantheus stock or one of its competitors? MarketBeat compares Lantheus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantheus include BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Lantheus compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Lantheus	18.05%	29.32%	15.00%

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 43.03%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 2.99%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioNTech has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

In the previous week, BioNTech and BioNTech both had 2 articles in the media. BioNTech's average media sentiment score of 1.38 beat Lantheus' score of 0.63 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.30

Summary

BioNTech beats Lantheus on 9 of the 16 factors compared between the two stocks.

How does Lantheus compare to Roivant Sciences?

Lantheus (NASDAQ:LNTH) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

In the previous week, Roivant Sciences had 9 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Roivant Sciences and 2 mentions for Lantheus. Roivant Sciences' average media sentiment score of 1.55 beat Lantheus' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Lantheus presently has a consensus target price of $101.86, indicating a potential downside of 2.99%. Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 11.23%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.30
Roivant Sciences	$8.26M	2,629.78	-$299.77M	-$0.60	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Roivant Sciences' net margin of -3,629.19%. Lantheus' return on equity of 29.32% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

Lantheus and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Lantheus compare to Insmed?

Insmed (NASDAQ:INSM) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Lantheus	18.05%	29.32%	15.00%

In the previous week, Insmed had 14 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Insmed and 2 mentions for Lantheus. Insmed's average media sentiment score of 1.21 beat Lantheus' score of 0.63 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	34.40	-$1.28B	-$5.75	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.30

99.1% of Lantheus shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Insmed presently has a consensus target price of $211.86, indicating a potential upside of 120.11%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 2.99%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Summary

Insmed beats Lantheus on 9 of the 17 factors compared between the two stocks.

How does Lantheus compare to Moderna?

Moderna (NASDAQ:MRNA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Moderna had 14 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for Moderna and 2 mentions for Lantheus. Moderna's average media sentiment score of 0.65 beat Lantheus' score of 0.63 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.46	-$2.82B	-$8.15	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.30

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Lantheus	18.05%	29.32%	15.00%

Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Moderna currently has a consensus target price of $36.60, indicating a potential downside of 34.84%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 2.99%. Given Lantheus' stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

75.3% of Moderna shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lantheus beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Lantheus	18.05%	29.32%	15.00%

Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.31	-$3.51B	-$0.26	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.30

Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 8.93%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 2.99%. Given Viatris' higher possible upside, analysts clearly believe Viatris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

79.9% of Viatris shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Viatris had 3 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Viatris and 2 mentions for Lantheus. Viatris' average media sentiment score of 0.80 beat Lantheus' score of 0.63 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Viatris on 11 of the 16 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.85B	$8.27B	$6.46B	$12.25B
Dividend Yield	N/A	2.50%	2.66%	5.66%
P/E Ratio	25.35	15.59	23.96	24.45
Price / Sales	4.43	7.46	519.37	138.35
Price / Cash	16.37	17.44	27.48	37.92
Price / Book	6.39	3.27	10.58	6.77
Net Income	$233.56M	$224.06M	$3.56B	$337.21M
7 Day Performance	5.02%	-1.47%	0.43%	2.12%
1 Month Performance	11.81%	4.81%	1.70%	3.99%
1 Year Performance	34.93%	1.63%	24.68%	28.92%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	2.6882 of 5 stars	$105.00 +0.3%	$101.86 -3.0%	+34.5%	$6.85B	$1.54B	25.35	1,193
BNTX BioNTech	4.5837 of 5 stars	$85.50 -2.9%	$129.56 +51.5%	-14.8%	$22.27B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.3543 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.3%	$20.56B	$8.26M	N/A	860	Positive News
INSM Insmed	3.415 of 5 stars	$94.17 -0.1%	$212.50 +125.7%	-1.3%	$20.42B	$606.42M	N/A	1,664	Positive News Analyst Forecast
MRNA Moderna	1.3443 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+95.5%	$18.82B	$1.94B	N/A	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors